- Hong Kong
- /
- Medical Equipment
- /
- SEHK:1302
3 SEHK Growth Stocks With Strong Insider Confidence
Reviewed by Simply Wall St
As global markets navigate heightened geopolitical tensions and fluctuating economic indicators, the Hong Kong market has shown resilience, with the Hang Seng Index climbing 10.2% amid optimism about China's supportive measures. In this context of cautious optimism, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence in a company's future prospects.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
Name | Insider Ownership | Earnings Growth |
Laopu Gold (SEHK:6181) | 36.4% | 32.6% |
Akeso (SEHK:9926) | 20.5% | 54.6% |
Fenbi (SEHK:2469) | 33.1% | 22.4% |
Xiamen Yan Palace Bird's Nest Industry (SEHK:1497) | 26.7% | 23.8% |
Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.8% | 69.8% |
Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
DPC Dash (SEHK:1405) | 38.1% | 104.2% |
Beijing Airdoc Technology (SEHK:2251) | 29.1% | 93.4% |
Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 69.7% |
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 109.2% |
We'll examine a selection from our screener results.
LifeTech Scientific (SEHK:1302)
Simply Wall St Growth Rating: ★★★★★☆
Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of HK$8.52 billion.
Operations: The company's revenue is primarily generated from its Structural Heart Diseases Business (CN¥523.01 million), Peripheral Vascular Diseases Business (CN¥725.13 million), and Cardiac Pacing and Electrophysiology Business (CN¥32.36 million).
Insider Ownership: 16%
LifeTech Scientific is poised for substantial growth with revenue expected to rise 21.5% annually, outpacing the Hong Kong market's 7.4%. Earnings are forecasted to grow significantly at 29.5% per year, although recent earnings showed a slight decline in net income from CNY 220.16 million to CNY 205.56 million for the half-year ending June 2024. Despite lower profit margins compared to last year, insider ownership remains high, aligning management interests with shareholders'.
- Click here and access our complete growth analysis report to understand the dynamics of LifeTech Scientific.
- According our valuation report, there's an indication that LifeTech Scientific's share price might be on the expensive side.
Meituan (SEHK:3690)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meituan is a technology retail company in the People's Republic of China, with a market cap of approximately HK$1.27 trillion.
Operations: The company's revenue is primarily derived from its Core Local Commerce segment, generating CN¥228.13 billion, and its New Initiatives segment, contributing CN¥77.56 billion.
Insider Ownership: 11.8%
Meituan demonstrates promising growth potential, with earnings projected to rise 26.1% annually, surpassing the Hong Kong market's average. Despite substantial insider selling recently, the company has engaged in significant share buybacks totaling HKD 7.17 billion this year, reflecting confidence in its valuation—currently trading at a discount to estimated fair value. Recent financial results show robust performance with net income doubling year-over-year for the first half of 2024.
- Dive into the specifics of Meituan here with our thorough growth forecast report.
- The valuation report we've compiled suggests that Meituan's current price could be inflated.
Angelalign Technology (SEHK:6699)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Angelalign Technology Inc. is an investment holding company that focuses on researching, developing, designing, manufacturing, and marketing clear aligner treatment solutions in the People’s Republic of China with a market cap of HK$12.23 billion.
Operations: The company generates revenue of CN¥1.72 billion from its Dental Equipment & Supplies segment.
Insider Ownership: 18.4%
Angelalign Technology's revenue is forecast to grow 15.3% annually, outpacing the Hong Kong market's average. Despite a decline in net income for the first half of 2024, with CNY 22.48 million compared to CNY 32.31 million last year, earnings are expected to rise significantly by 65.21% per year over the next three years. The company has not experienced substantial insider trading recently and maintains a low return on equity forecast of 6.2%.
- Take a closer look at Angelalign Technology's potential here in our earnings growth report.
- In light of our recent valuation report, it seems possible that Angelalign Technology is trading beyond its estimated value.
Where To Now?
- Click here to access our complete index of 47 Fast Growing SEHK Companies With High Insider Ownership.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:1302
LifeTech Scientific
An investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide.
Flawless balance sheet with high growth potential.